About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 6642 record(s)
Req # A-2020-001685
Adverse Reaction Reports (AERs). Report numbers: E2B_03315793, E2B_03396257, E2B_03397736, E2B_03397787, E2B_03282877, E2B_02353302, E2B_03324272, E2B_03402662, E2B_03279197.Organization: Health Canada
July 2021
Req # A-2020-001746
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03320875.Organization: Health Canada
July 2021
Req # A-2020-001832
Adverse Reaction Reports (AERs). Report numbers: E2B_03426776, 000924311, E2B_03437489, E2B_03508059, E2B_03326229, E2B_03488964, E2B_03423191, 000736893, 000916101.Organization: Health Canada
July 2021
Req # A-2020-001885
Adverse Reaction Reports (AERs) for Mesalazine. Report numbers: E2B_03460490, E2B_03495844, 928718, E2B_03406701, E2B_03453475, E2B_03485142, E2B_03421636, E2B_03496420, 927137, 924338, 927129.Organization: Health Canada
July 2021
Req # A-2020-001895
Adverse Reaction Reports (AERs) for Mezavant. Report numbers: E2B_03321791, 919523, 924749, E2B_03284156, E2B_03286468, E2B_03292641, E2B_03302640. (ADRs) for Vyvanse. Report numbers: E2B_03300503, E2B_03287086, E2B_03284951. (ADR) for C1…Organization: Health Canada
July 2021
Req # A-2020-001911
Adverse Reaction Reports (AERs). Report numbers: E2B_02759974, E2B_02760024, E2B_02760057, 000913680, 000908903, E2B_03478100, E2B_03486669, E2B_03486667, 000727436, 000727650, E2B_02718570, E2B_02741388, E2B_02854189, 000732554, 000732551,…Organization: Health Canada
July 2021
Req # A-2020-001923
Adverse Reaction Reports (AERs) for Abilify. Report numbers: E2B_03357016, E2B_03433811, E2B_03438670, E2B_03445919, E2B_03448513, E2B_03451979, E2B_03452092, E2B_03452152, E2B_03452156, E2B_03452168, E2B_03452227, E2B_03452236, E2B_03452237,…Organization: Health Canada
July 2021
Req # A-2020-001925
Adverse Reaction Reports (AERs) for Abilify. Report numbers: E2B_03459686, E2B_03419120, E2B_03443807, E2B_03448503, E2B_03448516, E2B_03452162, E2B_03452163, E2B_03452350, E2B_03452353, E2B_03452602, E2B_03459110.Organization: Health Canada
July 2021
Req # A-2020-001938
Adverse Reaction Reports (AERs) for Dexilant. Report numbers: E2B_03555157, E2B_03550160, E2B_03532951,931919. (ADRs) for Entyvio. Report numbers: 928967, E2B_03541743, E2B_03527627. (ADRs) for Vedolizumab. Report numbers: E2B_03558386,931660,…Organization: Health Canada
July 2021
Req # A-2020-001943
Adverse Reaction Reports (AERs) for Mesalazine. Report numbers: E2B_03530029, E2B_03535707, E2B_03522639, E2B_03593963, E2B_03623086, E2B_03596600, E2B_03624831, E2B_03580929, E2B_03567985, E2B_03532944.Organization: Health Canada
July 2021